Skip to main content
OpenTrials
Completed

NCT Number: NCT04977596

Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer

1. Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied; 2. The CT imaging findings of G3 stage PNET and pancreatic cancer were compared to establish a Logistic regression diagnostic model, and the survival analysis of the two was compared. 3. Cox regression was used to study the risk factors for survival prognosis of well-differentiated and poorly differentiated PNET based on CT image features

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuroendocrine Tumor of Pancreas Adenoma Adenoma, Islet Cell CT Carcinoma, Pancreatic Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Pancreatic Diseases Pancreatic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

About this study

According to the latest WHO Classification of Neuroendocrine Neoplasms (NET) in 2019, pancreatic neuroendocrine neoplasms (PNET) are divided into well-differentiated and poorly differentiated PNETs.The former is divided into G1, G2, and well differentiated G3.There are few studies on the survival outcomes of these two differentiated PNET types.The G3 imaging manifestations of the two types of differentiation have not been studied yet, and G3 PNET is often clinically misdiagnosed as pancreatic cancer, so it is necessary to differentiate the imaging manifestations and survival time of the two types.

A total of 71 patients with PNET in our hospital from January 2012 to January 2019 and 58 patients with pancreatic cancer from February 2014 to August 2015 were retrospectively collected. Complete survival time data of all patients after telephone follow-up were obtained.Since G3 PNET is very rare, the investigators enrolled 9 patients with G3 PNET in the First Affiliated Hospital of Zhejiang University School of Medicine and 7 patients with G3 PNET in the Affiliated Hospital of Air Force Military Medical University from January 2013 to October 2018.

CT images of PNET and pancreatic cancer were analyzed independently by two radiologists specializing in abdominal diagnosis, in which G3 lesions were evaluated simultaneously on MRI images and the others were evaluated only on CT images.Records clinical data and imaging characteristics: gender, age, tumor markers, tumor shape, size, tumor characteristics, edge, the expansion of the shrinking, pancreas, pancreatic pancreatitis, enhancement scan, arterial phase and portal phase lesions and the ratio of pancreatic parenchyma around, liver metastasis, peripheral vascular invasion, lymph node metastasis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis by pathology and detailed pathological information
  • Enhanced CT examination or biopsy were performed within 2 months before surgery
  • There was no preoperative radiotherapy or chemotherapy

Exclusion criteria

  • No Ki-67 index
  • CT value cannot be measured by ROI because of pancreatic atrophy and other reasons
  • No enhanced images or missing images

Treatment and study plan

No intervention

Other

Retrospective study without intervention

Primary outcomes

  1. Tumor size

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    Maximum surface size of the lesion (cm)

  2. Tumor location

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    Locations of the pancreas: head, neck, body and tail

  3. Number of lesions

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    Number of lesions

  4. Margin

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    well-defined or ill-defined

  5. tumor texture

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    solid；solid and cystic；complex cystic

  6. Pancreatic tail contraction

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    yes or no

  7. Complicated pancreatitis

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    yes or no

  8. Pancreatic duct/bile duct dilatation

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    yes or no

  9. Extrapancreatic tissue invasion

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    yes or no

  10. Hepatic metastasis

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    yes or no

  11. Lymphatic metastasis

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    yes or no

  12. CT value of pancreas plain scan

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    CT value of pancreas plain scan

  13. CT value of lesion plain scan

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    CT value of lesion plain scan

  14. CT value of pancreas artery phase

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    CT value of pancreas artery phase

  15. CT value of lesion artery phase

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    CT value of lesion artery phase

  16. CT value of pancreas portal phase

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    CT value of pancreas portal phase

  17. CT value of lesion portal phase

    Time frame: preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy

    CT value of lesion portal phase

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Collaborators

  • The First Affiliated Hospital of the Fourth Military Medical University
  • Zhejiang University

Registry information

Official study title

Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma

Important dates

Study start
2012
Primary completion
2019
Study completion
2019
First posted
Jul 27, 2021
Registry last updated
Jul 27, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.